Investigational Drug Information for Bufotenin
✉ Email this page to a colleague
What is the development status for investigational drug Bufotenin?
Bufotenin is an investigational drug.
There have been 6 clinical trials for Bufotenin.
The most recent clinical trial was a Phase 1 trial, which was initiated on August 1st 2024.
The most common disease conditions in clinical trials are Depressive Disorder, Depression, and Depression, Postpartum. The leading clinical trial sponsors are GH Research Ireland Limited and [disabled in preview].
There are two hundred and seventy-two US patents protecting this investigational drug and four hundred and ninety-one international patents.
Summary for Bufotenin
| US Patents | 272 |
| International Patents | 491 |
| US Patent Applications | 735 |
| WIPO Patent Applications | 372 |
| Japanese Patent Applications | 88 |
| Clinical Trial Progress | Phase 1 (2024-08-01) |
| Vendors | 19 |
Recent Clinical Trials for Bufotenin
| Title | Sponsor | Phase |
|---|---|---|
| Pharmacokinetics of GH001 Delivered Via a Proprietary Aerosol Delivery Device in Healthy Subjects | GH Research Ireland Limited | PHASE1 |
| Phase 2 Clinical Trial of GH001 in Bipolar II Disorder | GH Research Ireland Limited | Phase 2 |
| A Trial of GH001 in Patients With Treatment-resistant Depression | GH Research Ireland Limited | Phase 2 |
Clinical Trial Summary for Bufotenin
Top disease conditions for Bufotenin
Top clinical trial sponsors for Bufotenin
US Patents for Bufotenin
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Bufotenin | ⤷ Start Trial | Pharmaceutical compositions resistant to abuse | EGALET LTD. (London, GB) | ⤷ Start Trial |
| Bufotenin | ⤷ Start Trial | Target addressing system | Cortland Capital Market Services LLC | ⤷ Start Trial |
| Bufotenin | ⤷ Start Trial | Abuse-deterrent controlled release formulations | Patheon Softgels Inc. (High Point, NC) | ⤷ Start Trial |
| Bufotenin | ⤷ Start Trial | Opioid and attention deficit hyperactivity disorder medications possessing abuse deterrent and anti-dose dumping safety features | Pisgah Laboratories, Inc. (Pisgah Forest, NC) | ⤷ Start Trial |
| Bufotenin | ⤷ Start Trial | Enteric soft capsule compositions | Patheon Softgels Inc. (High Point, NC) | ⤷ Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Bufotenin
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Bufotenin | Australia | AU2010211376 | 2029-02-06 | ⤷ Start Trial |
| Bufotenin | Australia | AU2013257533 | 2029-02-06 | ⤷ Start Trial |
| Bufotenin | Canada | CA2751627 | 2029-02-06 | ⤷ Start Trial |
| Bufotenin | Denmark | DK2393487 | 2029-02-06 | ⤷ Start Trial |
| Bufotenin | European Patent Office | EP2393487 | 2029-02-06 | ⤷ Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
